CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort review

In a  multisite, retrospective cohort review of 308 children and young adults who received CD19-CAR, researchers found that CD19-CAR is effective in treating B-cell acute lymphoblastic leukemia in patients with extramedullary or central nervous system disease. These findings held particularly true in patients with low bone marrow disease burden; in patients with high bone marrow disease burden, concurrent extramedullary or central nervous system disease was associated with inferior outcomes.